Europe Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030
The Europe Guillain-Barre Syndrome Market would witness market growth of 4.4% CAGR during the forecast period (2023-2030).
The Germany market dominated the Europe Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $57,999.6 Thousands by 2030. The UK market is exhibiting a CAGR of 3.5% during (2023 - 2030). Additionally, The France market would experience a CAGR of 5.2% during (2023 - 2030).
The applications of the Guillain-Barre syndrome market encompass various aspects of diagnosis, treatment, supportive care, and rehabilitation, all aimed at improving patient outcomes and quality of life. Accurate and timely diagnosis of GBS is essential for initiating appropriate treatment and managing the condition effectively.
Moreover, nerve conduction studies (NCS) measure the electrical signal intensity and speed as they travel along peripheral nerves to assess nerve function. Abnormalities in nerve conduction velocities and amplitudes indicate nerve damage characteristic of GBS.
Likewise, specialized neurology clinics in Spain, such as Hospital Clínic de Barcelona or Hospital Universitario La Paz in Madrid, are dedicated to diagnosing and managing neurological disorders, including GBS. Therefore, the market is growing due to the expansion of the healthcare industry and the development of rehabilitation facilities in the region.
Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- PTC, Inc.
- AstraZeneca PLC
- Novartis AG
- Novo Nordisk A/S
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Merck & Co., Inc.
- Bristol Myers Squibb Company
By Therapeutics
- Intravenous Immunoglobulin
- Plasma Exchange
- Others
- Parenteral
- Oral
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Guillain-Barre Syndrome Market, by Therapeutics
- 1.4.2 Europe Guillain-Barre Syndrome Market, by Route Of Administration
- 1.4.3 Europe Guillain-Barre Syndrome Market, by Distribution Channel
- 1.4.4 Europe Guillain-Barre Syndrome Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
- 3.3 Porter Five Forces Analysis
- Chapter 4. Europe Guillain-Barre Syndrome Market by Therapeutics
- 4.1 Europe Intravenous Immunoglobulin Market by Country
- 4.2 Europe Plasma Exchange Market by Country
- 4.3 Europe Others Market by Country
- Chapter 5. Europe Guillain-Barre Syndrome Market by Route Of Administration
- 5.1 Europe Parenteral Market by Country
- 5.2 Europe Oral Market by Country
- Chapter 6. Europe Guillain-Barre Syndrome Market by Distribution Channel
- 6.1 Europe Hospital Pharmacies Market by Country
- 6.2 Europe Retail Pharmacies Market by Country
- 6.3 Europe Others Market by Country
- Chapter 7. Europe Guillain-Barre Syndrome Market by Country
- 7.1 Germany Guillain-Barre Syndrome Market
- 7.1.1 Germany Guillain-Barre Syndrome Market by Therapeutics
- 7.1.2 Germany Guillain-Barre Syndrome Market by Route Of Administration
- 7.1.3 Germany Guillain-Barre Syndrome Market by Distribution Channel
- 7.2 UK Guillain-Barre Syndrome Market
- 7.2.1 UK Guillain-Barre Syndrome Market by Therapeutics
- 7.2.2 UK Guillain-Barre Syndrome Market by Route Of Administration
- 7.2.3 UK Guillain-Barre Syndrome Market by Distribution Channel
- 7.3 France Guillain-Barre Syndrome Market
- 7.3.1 France Guillain-Barre Syndrome Market by Therapeutics
- 7.3.2 France Guillain-Barre Syndrome Market by Route Of Administration
- 7.3.3 France Guillain-Barre Syndrome Market by Distribution Channel
- 7.4 Russia Guillain-Barre Syndrome Market
- 7.4.1 Russia Guillain-Barre Syndrome Market by Therapeutics
- 7.4.2 Russia Guillain-Barre Syndrome Market by Route Of Administration
- 7.4.3 Russia Guillain-Barre Syndrome Market by Distribution Channel
- 7.5 Spain Guillain-Barre Syndrome Market
- 7.5.1 Spain Guillain-Barre Syndrome Market by Therapeutics
- 7.5.2 Spain Guillain-Barre Syndrome Market by Route Of Administration
- 7.5.3 Spain Guillain-Barre Syndrome Market by Distribution Channel
- 7.6 Italy Guillain-Barre Syndrome Market
- 7.6.1 Italy Guillain-Barre Syndrome Market by Therapeutics
- 7.6.2 Italy Guillain-Barre Syndrome Market by Route Of Administration
- 7.6.3 Italy Guillain-Barre Syndrome Market by Distribution Channel
- 7.7 Rest of Europe Guillain-Barre Syndrome Market
- 7.7.1 Rest of Europe Guillain-Barre Syndrome Market by Therapeutics
- 7.7.2 Rest of Europe Guillain-Barre Syndrome Market by Route Of Administration
- 7.7.3 Rest of Europe Guillain-Barre Syndrome Market by Distribution Channel
- Chapter 8. Company Profiles
- 8.1 F. Hoffmann-La Roche Ltd.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Segmental and Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 SWOT Analysis
- 8.2 Pfizer, Inc.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional & Segmental Analysis
- 8.2.4 Research & Development Expense
- 8.2.5 SWOT Analysis
- 8.3 PTC, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Segmental and Regional Analysis
- 8.3.4 Research & Development Expenses
- 8.3.5 SWOT Analysis
- 8.4 AstraZeneca PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expenses
- 8.4.5 SWOT Analysis
- 8.5 Novartis AG
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental and Regional Analysis
- 8.5.4 Research & Development Expense
- 8.5.5 Recent strategies and developments:
- 8.5.5.1 Partnerships, Collaborations, and Agreements:
- 8.5.6 SWOT Analysis
- 8.6 Novo Nordisk A/S
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental and Regional Analysis
- 8.6.4 Research & Development Expenses
- 8.6.5 SWOT Analysis
- 8.7 Takeda Pharmaceutical Company Limited
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Regional Analysis
- 8.7.4 Research & Development Expense
- 8.7.5 SWOT Analysis
- 8.8 Bayer AG
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 SWOT Analysis
- 8.9 Merck & Co., Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expenses
- 8.9.5 Recent strategies and developments:
- 8.9.5.1 Partnerships, Collaborations, and Agreements:
- 8.9.6 SWOT Analysis
- 8.10. Bristol Myers Squibb Company
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional Analysis
- 8.10.4 Research & Development Expenses
- 8.10.5 SWOT Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook